Updated EU CTIS Guide Offers Workaround To Protect ‘Commercially Confidential’ Dosing Data

EU regulators explain how sponsors who are running integrated Phase I/Phase II trials can overcome default transparency settings in the Clinical Trials Information System to protect the disclosure of dosing details if these contain commercially confidential information.